News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

Sign In

Radiologist Vacancies Remain High, Despite AI Advancements

A new analysis shows why models fall short in practice, how liability and equity issues slow adoption, and what lab leaders should consider as AI becomes a growing part of diagnostic workflows.

Artificial intelligence (AI) has made notable advances in medical imaging, but radiologists are not being displaced. For laboratory and diagnostic leaders, a recent analysis in Works in Progress highlights why AI has not replaced human expertise in radiology—and what this means for managing technology adoption in labs and hospitals.

In 2016, AI pioneer Geoffrey Hinton declared that “people should stop training radiologists now.” Since then, more than 700 FDA-cleared radiology AI models have entered the market, covering everything from stroke detection to lung cancer screening.

Companies such as Annalise.ai, Lunit, Aidoc, and Qure.ai offer tools that can identify dozens of diseases across modalities, reorder worklists, or generate structured draft reports. “On paper, radiology looks like the perfect target for automation,” the article noted, citing its reliance on digital images, pattern recognition, and quantitative benchmarks. Yet demand for radiologists has never been higher. In 2025, US residency programs offered a record 1,208 positions, and vacancy rates remain high as well.

Why Hasn’t AI Taken Over?

For leaders overseeing diagnostic services, three key elements are why AI has not replaced radiologists.

First, models struggle in real-world deployment. “Performance can drop by as much as 20 percentage points” when systems trained on narrow datasets are applied across different scanners, imaging protocols, or patient populations, the article explained. What works in a benchmark test may falter in a hospital with diverse workflows.

Second, liability and regulatory hurdles remain high. Assistive models that require physician review face fewer barriers, but autonomous systems must self-abort on poor image quality, identify unfamiliar equipment, and withstand rigorous scrutiny. Insurers have also drawn hard lines: one malpractice policy states that “coverage applies solely to interpretations reviewed and authenticated by a licensed physician; no indemnity is afforded for diagnoses generated autonomously by software.” Another bluntly imposes an “Absolute AI Exclusion.” For labs, this underscores the importance of risk management before deploying AI tools.

Photo credit: “Artificial Intelligence – Resembling Human Brain” by deepakiqlect is licensed under CC BY 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/2.0/?ref=openverse.

Photo credit: “Cancer” by davis.steve32 is licensed under CC BY 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/2.0/?ref=openverse.

Third, radiologists do much more than read scans. “Human radiologists spend a minority of their time on diagnostics and the majority on other activities, like talking to patients and fellow clinicians,” the commentary pointed out. Oversight of imaging protocols, interdisciplinary consultations, and patient communication all fall outside the reach of algorithms. Even as AI improves, demand for imaging may increase rather than decrease—a version of the Jevons paradox where greater efficiency leads to higher use. “The better the machines, the busier radiologists have become,” the article observed.

For laboratory leaders, the takeaway is not to fear replacement but to prepare for integration. AI tools are proving valuable in triaging urgent cases, flagging abnormalities, and drafting reports, but they remain narrow in scope—stroke, lung cancer, and breast lesions account for about 60% of models, yet represent only a fraction of total imaging work. As the article concluded, “Models can lift productivity, but their implementation depends on behavior, institutions and incentives.”

The challenge for labs is to create environments where AI augments human expertise rather than attempts to replace it. That means aligning technology adoption with clinical needs, providing training for staff, and working with insurers and regulators to ensure coverage and compliance.

For now, radiologists and the labs that support them are not going away. They are adapting, and AI will be a partner in that evolution.

—Janette Wider

Researchers Create Nanoparticle that Targets Cancer to Optimize MRI Scanning; New Technology Has Potential to Reduce Number of Tissue Biopsies and Pathology Testing

Researchers at Imperial College London report that their new nanoparticles make it possible for cancer to be visible in magnetic resonance imaging

Even as pathologists are working to develop more sensitive and accurate diagnostic tests for cancer, similar efforts are underway in radiology and imaging. In fact, one research team has developed a self-assembling nanoparticle that can adhere to cancer cells, thus making them visible in MRI scans and possibly eliminate the need for invasive tissue biopsies.

Clinical pathologists and medical laboratory managers will be interested in this research, which is being done at Imperial College London (Imperial). Researchers there have developed a self-assembling nanoparticle that targets cancer cells and makes them visible on magnetic resonance imaging (MRI) scans. (more…)

Start-up Company Hopes Its Revolutionary Hand-Held Device May Render Current MRI and Ultrasound Testing Obsolete

Venture capitalists are betting $100 million that an entrepreneur can develop an inexpensive and portable imaging device that can be used by office-based physicians

There’s a serious effort, funded by venture capitalists, to create a compact medical imaging device with the capabilities to disrupt the existing radiology profession. Developers intend to create a more accurate imaging technology that also costs much less than the expensive imaging systems in common use today.

Biomedical entrepreneur Jonathan Rothberg aims to create a new hand-held medical imaging device that can make MRI and ultrasounds significantly cheaper and more efficient, reported Wired magazine. Rothberg is founder of the Butterfly Network, Inc. 

Rothberg’s goal is to make it possible for office-based physicians to use a point-of-care imaging tool that costs just a couple hundred dollars. It might also help patients in poor regions of the world gain access to imaging tests and better healthcare. (more…)

Public Hospital in Phoenix Slashes Patient Self-Pay Prices by 50% to Increase Hospital Price Transparency

Maricopa Integrated Health System reports that price transparency pays off by reducing uncompensated care and increasing business

Arizona has a new law that requires hospitals, medical laboratories, diagnostic imaging facilities, ambulatory surgery centers, and urgent-care centers to publish the prices they charge self-pay and uninsured patients for the 50 most common inpatient and outpatient services. The law took effect on January 1, 2014.

News accounts report that just one hospital took steps to publish its prices earlier this year. Pathologists and clinical laboratory managers will find the experience of Maricopa Integrated Health System to be instructive, as hospital administrators there publicly state that this was the right thing to do for patients in their community. (more…)

GE Healthcare Pays $587 Million to Purchase Clarient, the Specialty Pathology and Cancer Testing Firm

GE’s Acquisition Considered A Sign Of More Deals To Come In The Clinical Laboratory Industry

Here’s more confirmation that anatomic pathology continues to be a big target on the radar screen of big healthcare corporations and Wall Street investors. Today, GE Healthcare, a unit of General Electric Company (NYSE: GE), disclosed it will pay $587 million to acquire Clarient, Inc. (NASDAQ: CLRT), the medical testing laboratory.

For pathologists and clinical laboratory managers, this is further confirmation that GE—one of the world’s major players in molecular imagin and radiology—intends to combine molecular diagnostic technologies used in anatomic pathology with its molecular imaging technologies used in radiology. In the press release about the acquisition, GE wrote that the addition of Clairent would help it create “new integrated tools for the diagnosis and characterization of cancer.”

(more…)

;